Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Trial ID or NCT#
NCT05844982
Status
NOT RECRUITING
Purpose
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Official Title
A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Investigator(s)
Prithvi Mruthyunjaya, MD, MHS
Ophthalmologic oncologist,
Retina specialist,
Ophthalmologist
Professor of Ophthalmology and, by courtesy, of Radiation Oncology
Contact us to find out if this trial is right for you.
Contact
Naz Jehangir
View on ClinicalTrials.gov
